Research view
Switch to patient viewKidney cancer: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Pick a target or a country to narrow the list.
- All targets
- PD-1 21
- PD-L1 11
- VEGF 10
- mTOR 1
- AKT 0
- VHL 6
- PI3K 0
- PSMA 10
- STAT3 0
- BAP1 1
- TP53 0
- JAK 0
- CTLA-4 4
- STING 1
- ALK 1
- EGFR 3
- TFEB 0
- ERK 0
- MYC 0
- YAP 0
- HIF-1 0
- AMPK 0
- CTNNB1 0
- MET 2
- B7-H3 2
- MAPK 0
- PPAR 0
- FGFR 1
- GLP-1 0
- GPC3 3
- HER2 2
- IL-6 0
- MMP-9 0
- PARP 1
- AXL 1
- BCL-2 0
- EZH2 0
- IDH 1
- NTRK 0
- PTEN 0
- BRAF 1
- CD19 1
- CDKN2A 0
- JNK 0
- KRAS 1
- LAG-3 0
- METTL3 1
- NLRP3 0
- NRF2 0
- PKM2 0
- ROS1 0
- TNF 0
- APOE 0
- BRCA1 0
- BRCA2 0
- BRD4 0
- CD20 0
- CDK4/6 0
- DPP-4 0
- FOXP3 0
Running research funding
Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.
NIH NCI · K99
Defining how mitochondrial metabolites reprogram cellular metabolism to control tumor growth
NIH NCI · R50
NIH NCI · R44
NIH NCI · R01
NIH NCI · R01
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
European Commission (Horizon Europe) · HORIZON-ERC
IDENTIfication and tracking of cancer-prone cells in KIdney Tubules (IDENTIKIT)
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-ERC
European Commission (Horizon Europe) · HORIZON-RIA
European Commission (Horizon Europe) · HORIZON-RIA
10 of 245 running projects, newest first. Listed amounts together: US$130.4m + €19.2m.
Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
No trial in this view states that it shares participant data.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 37
- Organoids 4
- Mendelian Randomization Analysis 22
- CRISPR-Cas Systems 8
- Gene Expression Profiling 97
- Sequence Analysis, RNA 2
- Whole Genome Sequencing 6
- Exome Sequencing 10
- Proteomics 25
- Metabolomics 12
- Mass Spectrometry 3
- Flow Cytometry 11
- Immunohistochemistry 95
- Liquid Biopsy 6
- Circulating Tumor DNA 8
- Xenograft Model Antitumor Assays 77
- Positron-Emission Tomography 14
- Magnetic Resonance Imaging 60
- Machine Learning 71
- Deep Learning 36
- Cohort Studies 67
- Genome-Wide Association Study 19
Metabolomic profiling of renal cell carcinoma to identify prognostic markers of metastasis.
Integrated metabolomics data analysis to generate mechanistic hypotheses with MetaProViz.
Urinary multi-omics reveal non-invasive diagnostic biomarkers in clear cell renal cell carcinoma.
Riemannian metric learning for alignment of spatial multiomics.
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed, NIH RePORTER, CORDIS. Machine-matched links are labelled.